News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
The startup plans to provide free technology to dental clinics upon registration.
Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Subscribe To Our Newsletter & Stay Updated
